ResearcherHarvard UniversityNo recent work listed
John R. Hornick
Matched on OpenAlex author ID A5039198380. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper
Papers 5
- Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochond… First author DOI 10.1186/s12885-016-3040-4↗
- Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Co-author DOI 10.1016/j.molonc.2014.03.005↗
- A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s10637-012-9866-y↗
- Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Co-author DOI 10.1016/j.surg.2012.05.014↗
- Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. Co-author DOI 10.1186/1756-9966-31-41↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- William G. Hawkins · 5 shared papers, 2012–2017 · strength 0.22
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- Paper Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. DOI 10.1016/j.molonc.2014.03.005↗
- Paper Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. DOI 10.1016/j.surg.2012.05.014↗
- Dirk M. Spitzer · 4 shared papers, 2012–2017 · strength 0.19
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- Paper Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. DOI 10.1016/j.molonc.2014.03.005↗
- Paper Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. DOI 10.1016/j.surg.2012.05.014↗
- Peter S. Goedegebuure · 4 shared papers, 2012–2014 · strength 0.15
- Paper Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. DOI 10.1016/j.molonc.2014.03.005↗
- Paper Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. DOI 10.1016/j.surg.2012.05.014↗
- Paper A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. DOI 10.1007/s10637-012-9866-y↗
- Carmen Abate · 2 shared papers, 2012–2017 · strength 0.11
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- Paper Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic canc… DOI 10.1186/1756-9966-31-41↗
- Maria Laura Pati · 1 shared paper, 2017 · strength 0.08
- Mauro Niso · 1 shared paper, 2017 · strength 0.08
- Yassar M. Hashim · 1 shared paper, 2014 · strength 0.04
- Steven M. Sorscher · 1 shared paper, 2013 · strength 0.03
- Albert Craig Lockhart · 1 shared paper, 2013 · strength 0.03
- Andrea Wang‐Gillam · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.